We speculate that while MARCKSL1 was prognostic in an earlier population, changes in chemotherapy guidelines have altered the overall survival and the specific need for prognostic factors in Norwegian breast cancer patients [1, 34]. This evidence concerns the gene MARCKSL1 and breast cancer.